Gary D. Glick

Founder, President & Chief Executive Officer Odyssey Therapeutics

Last Reviewed: September 25, 2026

Executive Summary

Gary D. Glick is the founder, President and Chief Executive Officer of Odyssey Therapeutics, a clinical-stage biopharmaceutical company in Boston developing oral medicines for autoimmune and inflammatory diseases. A chemist by training, he has spent the past decade founding and running drug-discovery companies and selling their programs to large drugmakers. At IFM Therapeutics he completed three program sales. He co-founded Scorpion Therapeutics, which Eli Lilly later bought for up to $2.5 billion. He founded Odyssey in April 2021 and took it public on Nasdaq in May 2026 under the symbol ODTX, raising $279 million in the offering. Its lead program, OD-001, an oral RIPK2 scaffolding inhibitor, has achieved proof of concept in a phase 2a trial in ulcerative colitis. Alongside Odyssey, he is Executive Chairman of IFM and Executive Chairman and interim CEO of the London-based Charm Therapeutics.

Career Highlights

• Founded Odyssey Therapeutics in April 2021 and has served as its President, Chief Executive Officer and a director since then.
• Led Odyssey’s May 2026 initial public offering: 15.5 million shares at $18.00 on the Nasdaq Capital Market, alongside a concurrent $25 million private placement to a TPG affiliate.
• Before the IPO, Odyssey raised about $726.5 million in gross proceeds from private financings, including a Series D of about $214 million that began in June 2025.
• As CEO of IFM Therapeutics from 2015 to 2019, took three programs from ideation to clinical development and completed three program sales generating $750 million to date, potentially more than $4.7 billion with milestones.
• Co-founded Scorpion Therapeutics in 2020. As CEO until February 2021 he grew it to nearly 50 employees and $270 million raised; Eli Lilly acquired Scorpion in 2025 for up to $2.5 billion in cash.
• As Chief Scientific Officer of Lycera, which he founded, completed more than $600 million of program partnering transactions.
• Executive Chairman of Charm Therapeutics since January 2022 and its interim CEO since June 2025; Executive Chairman of IFM since December 2019.

Professional Journey

Glick trained as an organic chemist. He earned his Ph.D. in organic chemistry at Columbia University and then held an NIH postdoctoral fellowship in organic chemistry at Harvard University.

His first company was Lycera Corporation, which he founded and where he served as Chief Scientific Officer. There he completed more than $600 million of program-partnering transactions. The model of building drug programs and selling or partnering them on to larger companies recurs through the rest of his career.

He applied that model most fully at IFM Therapeutics, which he founded and led as CEO from 2015 to November 2019. IFM was the first company to target the NLRP3 inflammasome and the STING pathway (stimulator of interferon genes). Under his leadership IFM took three programs from ideation to clinical development and sold them in three transactions that have generated $750 million so far and could reach more than $4.7 billion if milestones are met. He has been IFM’s Executive Chairman since December 2019.

In February 2020 he co-founded and launched Scorpion Therapeutics and was its CEO until February 2021. In that year Scorpion grew to nearly 50 employees and raised $270 million across two financings, and it started early discovery on several programs, including STX-478, a mutant-selective PI3K inhibitor. Eli Lilly acquired Scorpion in 2025 for up to $2.5 billion in cash.

He founded Odyssey Therapeutics in April 2021. The company’s thesis is that detailed knowledge of immunobiology, combined with medicinal and computational chemistry and structural biology, can identify and drug the signalling nodes that drive autoimmune and inflammatory disease. It concentrates on targets whose disease biology is supported by genetic, clinical or translational evidence. Its most advanced programs are OD-001, an oral RIPK2 scaffolding inhibitor that has achieved proof of concept in a phase 2a ulcerative colitis trial, and OD-002, an oral SLC15A4 inhibitor in IND-enabling studies. Earlier programs include a Treg-specific TNFR2 agonist, a bispecific TSLP and IL-33 antagonist, an IRAK4 scaffolding inhibitor and an IRF5 inhibitor developed with Terray Therapeutics. The board is chaired by Jeffrey Leiden, former CEO and now Executive Chairman of Vertex Pharmaceuticals. Odyssey operates from Boston and Ann Arbor, Michigan.

Odyssey’s route to the public markets took two attempts. It filed for an IPO in January 2025 and withdrew the registration that June. It then raised a Series D beginning in mid-2025 and priced its IPO in May 2026, selling 15.5 million shares at $18.00 for gross proceeds of $279 million, with TPG’s affiliate buying a further $25 million in a concurrent private placement. Glick continues to sign the company’s periodic reports as President and Chief Executive Officer. He also serves as Executive Chairman and, since June 2025, interim CEO of Charm Therapeutics, a London company developing menin inhibitors for acute myeloid leukemia. According to Odyssey’s filings, he gives Charm about ten hours a week and uses the time difference between London and Boston to do much of that work outside Boston business hours.

Education

Columbia University

Ph.D., Organic chemistry

He also completed an NIH postdoctoral fellowship in organic chemistry at Harvard University. This was a fellowship, not a degree.